Full-Time

Associate Director

Drug Substance Process Development

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

Compensation Overview

$152k - $202k/yr

+ Bonus + Equity

New Haven, CT, USA

Hybrid

Hybrid role; onsite once per week at HQ; travel up to ~20% for tech transfer/CMO activities.

Category
Biology & Biotech (2)
,
Requirements
  • BS/MS in Chemical Engineering, Biochemical Engineering, Pharmaceutical Engineering, or related scientific discipline, with 10–15 years of experience in biopharmaceutical or biotechnology industry, including process development, scale-up, and technology transfer
  • Demonstrated experience in drug substance process development for biologics (preferably monoclonal antibodies), with strong emphasis on downstream purification development, including chromatography, filtration, and viral clearance strategies across small- and large-scale systems
  • Proven track record in process scale-up, process characterization, and development of control strategies to support late-stage clinical and commercial readiness
  • Extensive experience leading and supporting technology transfer to contract manufacturing organizations, including preparation of technical packages and ensuring successful process implementation at external partners
  • Demonstrated ability to effectively manage and influence CDMOs from a development perspective, ensuring alignment on process performance, timelines, and deliverables
  • Strong knowledge of cGMP principles, ICH guidelines (Q8–Q11), and global regulatory expectations (FDA, EMA/CHMP) as they relate to process development and commercialization
  • Experience supporting CMC regulatory filings, including authoring or reviewing drug substance sections for INDs/IMPDs and BLAs/MAAs
  • Willingness to travel (up to ~20%) to support technology transfer activities and key development milestones at CDMOs
  • The role will require the ability to work in a hybrid capacity, once per week in the HQ office
Responsibilities
  • Provide technical leadership and oversight for drug substance process development activities, including process design, scale-up strategy, and technology transfer to CMOs
  • Serve as a subject matter expert for upstream and downstream process development, with particular emphasis on downstream purification strategy, process robustness, and scalability
  • Lead the design and execution of process characterization, process performance qualification (PPQ)-enabling studies, comparability assessments, and impurity control strategies to support clinical and commercial readiness
  • Define and translate process requirements into development reports, control strategies, and technology transfer packages to enable successful execution at external manufacturing partners
  • Collaborate with CMOs to ensure effective process transfer, scale-up, and process validation readiness, providing scientific and technical guidance rather than direct manufacturing oversight
  • Critically evaluate process and analytical data to identify risks, optimize performance, and resolve technical challenges throughout development
  • Develop and maintain strong relationships with external partners (CMOs, CROs, raw material suppliers, and consultants), ensuring alignment on development strategy and execution
  • Partner cross-functionally with Analytical Development, Quality, Regulatory, and Supply Chain to align on control strategy, specifications, and overall CMC strategy
  • Contribute to CMC regulatory submissions, including authoring and reviewing drug substance sections (INDs/IMPDs, BLAs/MAAs, and supporting documentation)
  • Identify program risks and critical path activities, and proactively develop mitigation strategies to ensure successful progression of development programs
  • Ensure that processes are designed for cGMP compliance and are aligned with FDA and EMA expectations, with clear line of sight to commercialization

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • PEMGARDA Q4 2025 revenue hit $17.2M, up 31% sequentially.
  • VYD2311 Phase 3 trial fully enrolled, data due mid-2026 with FDA Fast Track.
  • Appointed Harvard epidemiologist Michael Mina as Chief Medical Officer.

What critics are saying

  • Kahn Swick & Foti investigates officers over Adagio's 2021 IPO.
  • Low COVID-19 attack rates fail VYD2311 trial by mid-2026.
  • FDA revokes PEMGARDA EUA due to NB.1.8.1 variant escape in 2026.

What makes Invivyd unique

  • Proprietary platform combines viral surveillance, predictive modeling, and antibody engineering.
  • Develops vaccine-alternative monoclonal antibodies for immunocompromised patients.
  • Targets COVID-19, RSV, measles with pediatric-first approach via REVOLUTION program.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Invivyd who can refer or advise you

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-5%

2 year growth

-1%
Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

TipRanks
Nov 17th, 2025
Invivyd Announces Common Stock Offering

Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.

Stock Titan
Aug 22nd, 2025
Invivyd Closes $57.5M Public Offering

Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.